546 related articles for article (PubMed ID: 32717179)
1. Identifying prostate cancer and its clinical risk in asymptomatic men using machine learning of high dimensional peripheral blood flow cytometric natural killer cell subset phenotyping data.
Hood SP; Cosma G; Foulds GA; Johnson C; Reeder S; McArdle SE; Khan MA; Pockley AG
Elife; 2020 Jul; 9():. PubMed ID: 32717179
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer: Early Detection and Assessing Clinical Risk Using Deep Machine Learning of High Dimensional Peripheral Blood Flow Cytometric Phenotyping Data.
Cosma G; McArdle SE; Foulds GA; Hood SP; Reeder S; Johnson C; Khan MA; Pockley AG
Front Immunol; 2021; 12():786828. PubMed ID: 34975879
[TBL] [Abstract][Full Text] [Related]
3. Identifying the Presence of Prostate Cancer in Individuals with PSA Levels <20 ng ml
Cosma G; McArdle SE; Reeder S; Foulds GA; Hood S; Khan M; Pockley AG
Front Immunol; 2017; 8():1771. PubMed ID: 29326690
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. PSA-based machine learning model improves prostate cancer risk stratification in a screening population.
Perera M; Mirchandani R; Papa N; Breemer G; Effeindzourou A; Smith L; Swindle P; Smith E
World J Urol; 2021 Jun; 39(6):1897-1902. PubMed ID: 32747980
[TBL] [Abstract][Full Text] [Related]
6. Advancing Traditional Prostate-specific Antigen Kinetics in the Detection of Prostate Cancer: A Machine Learning Model.
Perera M; Smith L; Thompson I; Breemer G; Papa N; Patel MI; Swindle P; Smith E
Eur Urol Focus; 2022 Sep; 8(5):1204-1210. PubMed ID: 34920976
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?
Valberg M; Grotmol T; Tretli S; Veierød MB; Moger TA; Devesa SS; Aalen OO
Eur J Epidemiol; 2017 Jun; 32(6):511-520. PubMed ID: 27431530
[TBL] [Abstract][Full Text] [Related]
8. Markers and meaning of primary treatment failure.
Swindle PW; Kattan MW; Scardino PT
Urol Clin North Am; 2003 May; 30(2):377-401. PubMed ID: 12735513
[TBL] [Abstract][Full Text] [Related]
9. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
10. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; deKernion JB; Walsh PC; Scardino PT; Lange PH; Subong EN; Parson RE; Gasior GH; Loveland KG; Southwick PC
JAMA; 1998 May; 279(19):1542-7. PubMed ID: 9605898
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels.
Dinçel C; Caşkurlu T; Taşçi AI; Cek M; Sevin G; Fazlioğlu A
Int Urol Nephrol; 1999; 31(4):497-509. PubMed ID: 10668945
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer.
Murray NP; Reyes E; Fuentealba C; Orellana N; Morales F; Jacob O
Asian Pac J Cancer Prev; 2015; 16(13):5365-70. PubMed ID: 26225679
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.
Jyoti SK; Blacke C; Patil P; Amblihalli VP; Nicholson A
Cancer Causes Control; 2018 Jan; 29(1):87-92. PubMed ID: 28918559
[TBL] [Abstract][Full Text] [Related]
14. Population screening for prostate cancer and emerging concepts for young men.
Moul JW
Clin Prostate Cancer; 2003 Sep; 2(2):87-97. PubMed ID: 15040869
[TBL] [Abstract][Full Text] [Related]
15. Circulating PSA-containing macrophages as a possible target for the detection of prostate cancer: a three-color/five-parameter flow cytometric study on peripheral blood samples.
Leers MP; Nap M; Herwig R; Delaere K; Nauwelaers F
Am J Clin Pathol; 2008 Apr; 129(4):649-56. PubMed ID: 18343793
[TBL] [Abstract][Full Text] [Related]
16. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
[TBL] [Abstract][Full Text] [Related]
17. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
18. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
[TBL] [Abstract][Full Text] [Related]
19. Can natural killer cell activity help screen patients requiring a biopsy for the diagnosis of prostate cancer?
Tae BS; Jeon BJ; Lee YH; Choi H; Park JY; Bae JH
Int Braz J Urol; 2020; 46(2):244-252. PubMed ID: 32022514
[TBL] [Abstract][Full Text] [Related]
20. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
